List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Overview
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bristol-Myers Squibb Co
EpiAxis Therapeutics Pty Ltd
Evommune Inc
HotSpot Therapeutics Inc
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drug Profiles
AS-2521780 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit PRKCQ for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
englerin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPI-2xx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ewing Sarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PRKCQ for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Dormant Products
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Astellas Pharma Inc, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by EpiAxis Therapeutics Pty Ltd, 2021
Pipeline by Evommune Inc, 2021
Pipeline by HotSpot Therapeutics Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Companies Mentioned
• Astellas Pharma Inc
• Bristol-Myers Squibb Co
• EpiAxis Therapeutics Pty Ltd
• Evommune Inc
• HotSpot Therapeutics Inc